Towards these ends, many studies identified factors involved in drug resistance and developed multigene expression signatures to predict ccRCC outcomes and response to Sunitinib, and mutations in tumor suppressors (TP53, PBRM1 and BAP1) have also been shown to contribute to poor response to Sunitinib [7–11]. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.